グルココルチコイドは,GILZ媒介によるERK阻害により,グリブロスタモ細胞におけるPD- L1をダウン調節する
Sabrina Adorisio1, Giorgia Renga2, Domenico Vittorio Delfino1,2
1Section of Pharmacology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
Biomedicines
|August 28, 2025
まとめ
デキサメタゾンは,細胞系によって免疫回避に異なった影響を及ぼします. U87細胞では,GILZ- ERK経路でPD- L1を抑制するが,U251細胞ではそれを上調し,腫瘍増殖と免疫反応に影響する.
科学分野:
- 神経腫瘍学
- 免疫学
- 分子生物学
背景:
- デキサメタゾン (DEX) のようなグルココルチコイド (GC) は,膠芽細胞腫 (GBM) 腫れを治療しますが,その免疫効果は不明です.
- プログラムされた死亡リガンド1 (PD-L1) などの免疫チェックポイントは,腫瘍の免疫回避に不可欠です.
研究 の 目的:
- グリオブラストーマ細胞におけるPD-L1およびGILZ発現に対するDEXの影響を調査する.
- グルココルチコイド受容体 (GR),GILZ,PD-L1を含む調節経路を解明する.
主な方法:
- U87とU251のグリオブラストーマ細胞系をDEXで治療する.
- PD-L1とGILZの発現レベルの評価
- ERKのリン酸化と細胞サイクル進行の分析
- 遺伝子サイレンスとGILZの過剰発現の研究
主要な成果:
- 両方の細胞系で一貫してGILZ発現を誘導した.
- DEXは,U87細胞でPD- L1を抑制し,U251細胞でPD- L1を上調した.
- U87細胞では,DEX誘発のPD- L1抑制は,より速い細胞サイクル進行と相関していた.
- GILZ-ERK経路は,DEXによるPD-L1の調節に関与していた.
結論:
- グリオブラストーマ細胞における新しいGR- GILZ- PD- L1制御軸が特定されました.
- DEXはPD-L1に文脈依存的な影響を及ぼし,免疫回避と増殖に影響を与えます.
- この発見は,GBM療法におけるGILZ調節に関するさらなるin vivo研究を支持する.
さらに関連する動画
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
15.9K
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
8.4K
関連する概念動画
GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
GPCR Desensitization
6.4K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.4K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
